- Agreement Calls for 50/50 Global Profit Share for Multiple New Molecules - Companies Plan to Explore Broad Therapeutic Potential of AIM Class ABBOTT PARK, Ill. and IRVING, Texas, Dec. 12, 2011 ...

Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat ...

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Reata Pharmaceuticals, Inc., a ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F ...

A group of 27 servers and bartenders have filed a lawsuit alleging that the two Reata Restaurants in Texas are illegally forcing them to pay for business expenses that ought to be the responsibility ...

Reata Pharmaceuticals has done its homework in responding to the FDA’s concerns about an application for its nerve disorder drug. But now the biotech has to sit tight for an extra three months while ...

As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 ...